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Mitochondrial damage with release of cytochrome c is implicated in cell death signalling pathways. To examine mitochondrial
function in apoptotic cells, we applied high-resolution respirometry to human leukemia cells arrested in the G1- and S-phase by
exposure to the glucocorticoid dexamethasone and nucleotide analogue gemcitabine. At 30% apoptosis, opposite effects were observed
on respiratory capacity (71% and 131% of controls, respectively). These changes correlated with alterations in cell size, cytosolic, and
mitochondrial marker enzymes. Mitochondrial ATP production and membrane potential were maintained in all treatments, as deduced
from high respiratory uncoupling control ratios (UCR). Bcl-2 over-expression did not prevent apoptosis after gemcitabine-treatment,
but protected dexamethasone-treated cells from apoptosis, without fully preventing the decline of respiration and cell size. These
results, therefore, provide conclusive evidence that alterations in respiratory capacity and enzyme activities per cell are mainly caused
by opposite changes in cell size, occurring upon cell cycle arrest triggered by dexamethasone and gemcitabine in the early phase of
apoptosis.
D 2003 Elsevier B.V. All rights reserved.Keywords: Apoptosis; Dexamethasone; Gemcitabine; Mitochondrial respiratory control; Cell cycle1. Introduction
A variety of ill-defined death signals act on mitochondria
to induce release of apoptogenic factors such as cytochrome
c, the AIF or Smac/Diablo, from the intermembrane space to
the cytosol and/or the nucleus [1,2]. These proteins initiate
apoptosis by activating caspases, nuclear endonucleases or
by neutralizing inhibitors of the apoptotic cascade. Mito-
chondrial sensitivity to apoptogenic signals is controlled by
pro- and anti-apoptotic proteins of the Bcl-2 family [3–6].
Bcl-2 over-expression is a crucial event in some malignan-
cies, e.g. follicular lymphomas, and thus diminishes the
efficacy of clinically important chemotherapeutics. Various0167-4889/$ - see front matter D 2003 Elsevier B.V. All rights reserved.
doi:10.1016/S0167-4889(03)00105-8
Abbreviations: COX, cytochrome c oxidase; CS, citrate synthase; FCCP,
carbonylcyanide p-trifluoromethoxy phenylhydrazone; LDH, lactate dehy-
drogenase; TMPD, N,N,NV,NV-tetramethyl-p-phenylenediamine dihydro-
chloride; UCR, uncoupling control ratio
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E-mail address: erich.gnaiger@uibk.ac.at (E. Gnaiger).models of cytochrome c release have been proposed with
opposite implications on mitochondrial membrane potential,
(i) release after mitochondrial permeability transition with
dissipation of mitochondrial membrane potential and loss
of respiratory function [7], (ii) release through a specific
pore before disrupture of membrane potential, with partial
preservation of mitochondrial function which can be revers-
ibly rescued by exogenous cytochrome c [8,9], and (iii)
release after hyperpolarization [10,11]. In spite of intensive
research, key questions remained unresolved concerning
the primary involvement of alterations in mitochondrial
membrane potential and oxidative phosphorylation in
programmed cell death. Various signals implicated in apop-
tosis lead to induction of cell cycle arrest, which provides
time and energy for repair, or ultimately to the execution of
cell death. Over the cell cycle, a 2-fold change in cell size is
accompanied by corresponding changes of mitochondrial
content [12]. Cell cycle arrest caused by apoptogenic drugs
interacts with mitochondrial alterations, specifically related
to programmed cell death. In this study, apoptosis was
triggered by two chemotherapeutic agents: the glucocorti-
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pendent pathway [13,14], and the cytidine analogue gemci-
tabine [15,16]. Human acute lymphoblastic CCRF-CEM
leukemia cells with transgenic Bcl-2 expression were used
as a model system. Corresponding to cell cycle arrest in the
G1- and S-phase, respectively, cellular respiratory capacities
were affected in opposite ways by these apoptogenic drugs.
Respiratory function and the coupling of electron transport
to oxidative phosphorylation were analysed by high-resolu-
tion respirometry. States of highly coupled respiration were
indicated by stimulation of cellular oxygen consumption
after uncoupling with carbonylcyanide p-trifluoromethoxy
phenylhydrazone (FCCP). To distinguish between specific
mitochondrial defects and respiratory alterations related to
the cell cycle and cell size, respiratory rates were normalized
with respect to cell volume and protein content. In addition,
cellular respiratory capacity was related to activities of
marker enzymes for (i) the inner mitochondrial membrane
(cytochrome c oxidase (COX), partially mitochondrial
encoded), (ii) the mitochondrial matrix (citrate synthase
(CS), nuclear encoded; Ref. [17]), and (iii) the cytosol
(lactate dehydrogenase (LDH)). These approaches point to
the importance of changes in cell size and cellular mito-
chondrial content in response to chemotherapeutic drugs in
particular and ill-defined stressors in general when studying
changes in mitochondrial and enzymatic activities during
cell cycle arrest and apoptosis.Fig. 1. Apoptosis and uncoupled respiration in leukemia cells with (+) and
without ( ) Bcl-2 over-expression as a function of treatment with
dexamethasone (D; 100 nM for 48 h) or gemcitabine (G; 80 nM for 24 h)
and in controls (C). (A) Bcl-2 over-expression exerted a protective effect
against programmed cell death triggered by dexamethasone (D+), but was
ineffective in gemcitabine treatment. (B) Respiration per 106 cells decreased
in lymphocytes after incubation with dexamethasone, but increased after
incubation with gemcitabine. Uncoupled respiration was measured after
addition of 2 AM FCCP to cells suspended in mitochondrial respiration
medium. (*) Significant differences between controls and corresponding
incubated cells (*P< 0.05; **P < 0.01). (#) Differences between cells with
and without Bcl-2 over-expression were found only in dexamethasone-
treated cells (#P < 0.05).2. Materials and methods
2.1. Cell lines, culture conditions and reagents
CEM-C7H2 is a highly GC-sensitive sub-clone of the T-
ALL cell line CCRF-CEM C7. C7H2-10E1 is a sub-clone
with a tetracycline-repressed expression (‘‘tet-off system’’)
of transgenic Bcl-2 [5]. All cells were maintained in RPMI
1640 (PAA Laboratories GmbH, Teddington Middlesex,
UK) supplemented with 10% heat-inactivated tetracycline-
free fetal calf serum (PAA Laboratories), 2 mM L-glutamine
(Gibco, Grand Island, NY), 100 units/ml penicillin (Gibco)
and 100 Ag/ml streptomycin (Gibco) in a humified atmo-
sphere of 95% air and 5% CO2 at 37 jC in a Heraeus
incubator (Newtown, CT). The Bcl-2 gene was repressed by
the addition of 200 nM doxycycline (stored as 10 mM stockTable 1
Ratios of cell size, enzyme activities and respiration in cells exposed to dexameth
( ) Bcl-2 over-expression
Protein Volume LDH
D /C 0.64F 0.05 0.83F 0.04 0.60F 0.12
D+/C + 0.72F 0.04 0.83F 0.03 0.63F 0.09
G /C 1.38F 0.21 2.17F 0.24 1.36F 0.04
G+/C + 1.16F 0.26 1.72F 0.21 1.23F 0.16
Approximately 30% DNA was in the sub G1-phase in D , G and G+ cells.solution in phosphate-buffered saline). All reagents were
obtained from Sigma (St. Louis, MO) unless indicated
otherwise.asone (D) or gemcitabine (G) in relation to controls (C) with (+) or without
CS COX Uncoupled Coupled
0.76F 0.14 0.77F 0.15 0.71F 0.13 0.65F 0.16
0.68F 0.07 0.87F 0.14 0.84F 0.07 0.82F 0.15
1.52F 0.27 1.49F 0.34 1.31F 0.25 1.41F 0.25
1.43F 0.33 1.37F 0.45 1.38F 0.31 1.28F 0.33
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For experiments 3 105 cells/ml of mid-log cultures
were centrifuged and resuspended in fresh medium. Ap-
optosis was triggered by incubation in either gemcitabine
(24 h; 80 nM, dissolved in 0.9% NaCl), or dexamethasone
(36–48 h; 100 nM, dissolved in ethanol). For determina-
tion of apoptosis and cell cycle profiles, 2 105 cells
were centrifuged and resuspended in 200 Al of a hypo-
tonic fluorochrome solution (50 Ag/ml propidium iodide,
0.1% sodium citrate, 0.1% Triton X-100; Ref. [18]). Cells
were equilibrated at 4 jC in the dark overnight and
analysed by flow cytometry (FACS Calibur Becton Dick-
inson, San Jose, CA). Cell debris was eliminated by
forward and side scattering. Fluorescence 2 was measured
by linear acquisition, and cell cycle profiles were analysed
by ModFit zooming into the gate for non-apoptotic cells.
2.3. Spectrophotometric determination of enzyme activities
For determination of enzyme activities, 100 Al (1105
cells) were pipetted from the oxygraph chambers at the
beginning of an experiment, frozen in liquid nitrogen and
applied in the assay. The activity of CS was measured
spectrophotometrically at 30 jC as described [17]. LDH
activity was measured at 340 nm and 30 jC [19] in a 0.1
M Tris–HCl buffer (Merck, West Point, PA) with 0.25%
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expression (C—controls, D—dexamethasone-treated cells, G—gemcitabine-treated
titrations (final concentration, 1 and 2 AM) of cells in mitochondrial medium R05.
titrations (10 AM) of permeabilised cells in mitochondrial medium R05 with TMTriton X-100 (Serva, Vienna, Austria) at pH 7.1, with 10
mM pyruvate and 0.3 mM NADH (Fluka, St. Louis, MO).
2.4. Cell volume and protein determination
Cell number and volume were analysed in a CASY1 TT
cell counter (Scha¨rfe System, Reutlingen, Germany), using
100-Al samples of suspended cells which were diluted in 10
ml isotonic CASY solution. Events in the range of 6–30 Am
diameter were included in the calculation.
Samples for protein measurements were washed three
times with phosphate buffered saline (PAA Laboratories),
the cell number was determined, and samples were frozen in
liquid nitrogen. Protein content was measured in a Bradford
assay (Bio-Rad, Hercules, CA) using BSA as a standard in
the linear range of 5–0.31 Ag BSA/ml.
2.5. High-resolution respirometry
The function of the respiratory chain was analysed by
high-resolution respirometry in a two-channel titration in-
jection respirometer at 37 jC (Oroboros Oxygraph, Inns-
bruck, Austria; Ref. [20]) as described [21]. Briefly, cells
were washed and resuspended in a mitochondrial respiration
medium MiR05 (110 mM sucrose, 0.5 mM EGTA, 3.0 mM
MgCl2, 80 mM KCl, 60 mM K-lactobionate, 10 mM
KH2PO4, 20 mM Taurine, 20 mM Hepes, 1.0 g/l BSA,s and cytochrome c control ratios in CEM cells without ( ) Bcl-2 over-
cells). (A and B) Traces of oxygen concentration and respiration in FCCP
(C and D) Traces of oxygen concentration and respiration in cytochrome c
PD, ascorbate and antimycin A.
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step titration up to 2 AM. Complex III was inhibited with 2.5
AM antimycin A. Complex IV respiration was measured in
the presence of 500 AM N,N,NV,NV-tetramethyl-p-phenyl-
enediamine dihydrochloride (TMPD) and 2 mM ascorbate,
after permeabilisation of the cell membrane with digitonin
(10 Ag/106 cells). Subsequently, the activity of COX was
determined after addition of 10 AM cytochrome c (horse
heart, Boehringer Mannheim, Germany).
2.6. Statistics
Differences between controls and incubated cells within
experimental groups were analysed by a Wilcoxon test,
between experimental groups by Mann–Whitney U-tests,
independent of a normal distribution. Significance was
considered at P < 0.05.3. Results
3.1. Apoptosis and viability
Drug exposures were chosen to obtain approximately
30% DNA in the sub G1-phase in cells without Bcl-2
protection (Fig. 1A). Bcl-2 over-expression did not delay
or prevent apoptosis after gemcitabine treatment (31F13%
and 34F 11% in G+ and G , with and without Bcl-2 over-
expression, respectively). In contrast, apoptosis was effec-
tively retarded by Bcl-2 over-expression after exposure to
dexamethasone (9F 4% versus 26F 7% in D+ and D ,
with and without Bcl-2 over-expression, respectively;
P < 0.01). Except for one experiment, the fraction of apo-
ptotic DNA was identical in D+ and controls. Spontaneous
apoptosis was 4F 1% in controls, independent of Bcl-2
over-expression (C+ and C ; Fig. 1A). Trypan blueFig. 3. Constant respiratory ratios, maintained respiratory rates per unit COX
activity and constant relation between COX and citrate synthase (CS) activity
in leukemia cells after treatment with dexamethasone (D) or gemcitabine (G),
with (+) or without ( ) Bcl-2 over-expression. (A) Respiration of cells
before uncoupling (endogenous respiration) and after uncoupling with FCCP
(uncoupled respiration). The linear slope with zero intercept indicates a
constant and high uncoupling control ratio (UCR= 2.50F 0.24; N = 53) in
controls and all experimental groups. Dexamethasone decreased and
gemcitabine increased endogenous and uncoupled respiration proportionally.
S.D. is shown by error bars. Dashed lines show 95% confidence intervals of
the linear regression line. (B) In all treatments, respiration per COX activity
was identical in controls and incubated cells, both in the coupled
(endogenous) or uncoupled state. (C) COX activity correlated with CS
activity in all treatments within the range of identity. The line of identity is the
linear extrapolation between the zero intercept and the control C . The
range of identity spans the variability defined by the S.D. of results for C.
Dexamethasone decreased COX- and CS-activities, whereas gemcitabine
increased both enzyme activities. For determination of COX activity,
uncoupled respiration was stimulated with 0.5 mM TMPD, 2 mM ascorbate
and 10 AM cytochrome c in the presence of 2.5 AM antimycin A. S.D. is
shown by error bars.exclusion was constant at >97% in all groups, indicating
preservation of plasma membrane integrity and viability in
apoptotic cells.
3.2. Mitochondrial function
Uncoupled respiration as an index of respiratory capacity
was decreased in dexamethasone-treated cells. This reduc-
tion of uncoupled respiration was significantly more pro-
nounced in D cells than in non-apoptotic D+ cells (Fig.
1B). In comparison to dexamethasone, gemcitabine exerted
Fig. 4. Uncoupled respiration (A), CS activity (B), and LDH activity (C) as
a function of cell protein content. For treatments and line of identity see Fig.
2. Maximum activities of the mitochondrial respiratory chain (uncoupled
respiration), the mitochondrial marker enzyme CS, and the cytosolic marker
enzyme LDH were changed in opposite ways by dexamethasone and
gemcitabine treatment. All variations were proportional to alterations in cell
size, independent of apoptosis.
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1.4-fold relative to controls (Table 1). Despite the similar
degree of apoptosis in D and G cells, uncoupled
respiration differed by a factor of 2.1–2.7 (G /D ).
Transgenic Bcl-2 expression had no detectable effect on
uncoupled respiration in gemcitabine-treated cells and con-
trols (Fig. 1B). The ratio of uncoupled to endogenous
respiration was calculated after a two-step titration with
FCCP (Fig. 2A and B). This uncoupling control ratio (UCR)
was constant in all experimental groups and controls (2.50F
0.24; N = 53).
Cytochrome c release was detected indirectly by stimu-
lation of respiration after addition of 10 AM cytochrome c to
permeabilised cells in the presence of TMPD+ ascorbate,
antimycin A, and the uncoupler FCCP (Fig. 2C and D). The
respiratory cytochrome c control ratio was calculated as the
ratio of respiration after and before addition of cytochrome
c [17]. No significant stimulation by cytochrome c was
observed in controls. In incubated cells without over-expres-
sion of Bcl-2 (D and G ), the respiratory cytochrome
c control ratio was slightly but significantly increased
above 1.0 (1.14F 0.13 and 1.07F 0.04), whereas no signif-
icant cytochrome c effect was found in Bcl-2 over-express-
ing cells (cytochrome c control ratios were 1.09F 0.13 and
1.04F 0.12 in D+ and G+ cells).
Importantly, uncoupled respiration changed as a linear
and proportional function of endogenous respiration after
incubation with dexamethasone or gemcitabine, with con-
trols taking an intermediate position (Fig. 3A). These
results provide direct evidence for a high and constant
mitochondrial coupling state in the early phase of apopto-
sis. This excludes a decline in mitochondrial membrane
potential in the bulk of mitochondria, induced by a per-
meability transition, despite a significant cytochrome c
release (Fig. 2C and D).
Although dexamethasone or gemcitabine induced re-
markable changes in cellular respiration (Fig. 1B), these
differences cancelled out when relating endogenous or
uncoupled respiration to activity of COX (Fig. 3B). COX
activity, in turn, correlated linearly with CS activity in all
treatments, closely corresponding to the line of identity
(Fig. 3C). The line of identity was defined as the COX/CS
ratio in control cells without Bcl-2 over-expression (C ).
The only deviation from this line of identity was observed
in D+ cells with a significantly higher COX/CS ratio. In
general, COX and CS activities were down-regulated after
dexamethasone exposure but up-regulated after gemcitabine
treatment, indicating opposite changes in mitochondrial
content per cell.
3.3. Changes in cell size and cell cycle arrest
Uncoupled respiration, CS and LDH activities changed
with cellular protein content, closely following the line of
identity as defined by the control cells C (Fig. 4A–C).
This demonstrates that (i) mitochondrial content varied asa function of cell size at constant mitochondrial density,
and (ii) LDH activity correlated with cell size independent
of apoptosis and Bcl-2 over-expression. Conversely, the
ratio was constant between the mitochondrial matrix
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LDH.
These changes in cell size were closely linked to cell
cycle arrest. Lymphoblasts in continuous culture showed the
typical cell cycle profile for proliferating cells, with a
majority in G1, and the remaining cells distributed about
equally between the S- and G2/M-phases (Fig. 5A and C).
The cells remaining non-apoptotic after oncogenic treatment
(ca. 70%; Fig. 1A) were arrested in G1 with dexamethasone,
but in the S-phase with gemcitabine (Fig. 5B and D). Bcl-2
over-expression did not affect cell cycle arrest.
Table 1 summarizes changes in cell size and cor-
responding alterations in enzyme activities and respiration
in terms of ratios between dexamethasone and cor-
responding controls and gemcitabine-treated cells and con-
trols. These results were obtained in strictly parallel
experiments. In dexamethasone-treated cells, cell size and
activities were reduced 0.6- to 0.9-fold. In contrast, cell
protein and activities in gemcitabine-treated cells increased
1.2- to 1.5-fold. Cell volume increased to a larger extent
than cell protein particularly in G+. The major factor,
therefore, was the quantitative change of cells size deter-
mining cell-specific alterations of mitochondrial respiration
and enzyme activities in all treatments.Fig. 5. Cell cycle profiles of leukemia cells, determined by FACS analysis within
(C ) and corresponding treatments with dexamethasone (A and B) and gemcitab
over-expression show identical cell cycle distributions. The positions of the peaks
and G2/M). Dexamethasone arrests cells in G1, whereas cells are arrested in the s4. Discussion
The protective function of Bcl-2 over-expression against
apoptosis is widely reported [6,22,23]. In the present study,
Bcl-2 over-expression prevented or delayed apoptosis in
glucocorticoid-treated leukemia cells, confirming results
reported for various cell types [3–5]. In contrast to dexa-
methasone, gemcitabine induced apoptosis independent of
Bcl-2 over-expression. This is consistent with results reported
for another haematopoietic malignancy, i.e. multiple myelo-
ma cells [24], but contrary to the protective effect of Bcl-2
content against gemcitabine in solid tumors [25]. Gemcita-
bine, therefore, may be the drug of choice in cancer therapy of
lymphomas with Bcl-2 translocation and over-expression. In
the latter case, cells may undergo apoptosis by direct activa-
tion of caspase 8 through the cross-linking of Fas/Apo-1/
CD95, which in turn causes activation of caspase 3 [26].
Release of cytochrome c to the cytosol is well documented for
the activation of caspases and induction of apoptosis, both of
which are reduced by Bcl-2 over-expression [22,27]. In our
experiments, a small fraction of cytochrome cwas released in
apoptotic cells, as shown by the indirect approach of respi-
rometric stimulation. The constant UCR shows that the major
fraction of mitochondria remained functionally intact, with-the gate of non-apoptotic cells. Representative scans are shown for controls
ine (C and D) of cells without Bcl-2 over-expression, and cells with Bcl-2
of the cell cycle phases depend on the channel settings as indicated (G1, S,
ynthesis phase (S) after treatment with gemcitabine.
Fig. 6. Cell respiration influenced by changes of metabolic state (stimulated
ATP turnover or metabolic arrest), mitochondrial quality (mitochondrial
injuries), mitochondrial concentration (as a function of mitochondrial size
or density), or cell size at a constant ratio of mitochondrial/cellular protein.
In particular, average cell size of a bulk population in logarithmic growth
changes when cell cycle arrest occurs. Cells start the growth phase (G1) at
half of the size of cells in the mitotic phase (M). Dexamethasone arrests
cells in G1 and inhibits growth. A large size is reached in the synthesis
phase (S), where cells are arrested when treated with gemcitabine.
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early phase of apoptosis. While mitochondrial permeability
transition leading to uncoupling and consequential disruption
of the outer mitochondrial membrane may cause cytochrome
c release, several mechanistic models explain cytochrome c
release without injury of the inner mitochondrial membrane
[7–9,28–30]. In apoptotic cells not protected by Bcl-2 over-
expression, stimulation of complex IV respiration by exter-
nally added cytochrome c indicates cytochrome c release and
hence reduction of respiratory capacity. This inhibition, how-
ever, amounted to only 5–8%. Our results are consistent with
the pathway of cytochrome c release independent of a
permeability transition, although the complete damage and
loss of respiratory activity in a small fraction of mitochondria
cannot be excluded. Importantly, mitochondrial heterogene-
ity is well-documented in apoptotic cells [31–33]. Thirty
percent of apoptosis is compatible with merely 5–8% stim-
ulation of respiration by external cytochrome c if in any
apoptotic cell only 20% of mitochondria are cytochrome c-
depleted, or if a partial cytochrome c release has occurred
above the kinetic threshold [42]. In the latter case, cellular
respiration through the entire mitochondrial electron trans-
port chain (before and after uncoupling) is inhibited by cyto-
chrome c release to even a lesser extent than indicated by our
cytochrome c test with TMPD+ ascorbate, owing to the ex-
cess capacity of COX relative tomaximum pathway flux [42].
The present investigation shows that dexamethasone
and gemcitabine exert strong effects on cellular respira-
tion, in entirely opposite ways but without any changes in
the coupling state. The more than 2-fold difference of
respiration between cells treated by these agents warrants
explanation. These alterations could be the result of (i)
mitochondrial injuries, (ii) variations in metabolic state,
(iii) changes in mitochondrial density, or (iv) changes in cell
size which may be pathological or strictly correlated to cell
cycle arrest (Fig. 6). In dexamethasone-incubated cells, Bcl-
2 over-expression prevented the reduction of respiration per
cell to some extent. Glucocorticoid-induced inhibition of the
respiratory chain, e.g. by direct interaction with mitochon-
drial membranes [34], reduces mitochondrial capacity. This
was not the case in our study using a low concentration of 0.1
AM dexamethasone for the following reasons: (i) cellular
respiration and activities of marker enzymes for the inner
mitochondrial membrane (COX) and mitochondrial matrix
(CS) changed in line with the cytosolic marker LDH and
total cellular protein content. Thus, respiratory activity per
unit mitochondria (constant respiration/CS-activity and res-
piration/COX-activity), and mitochondrial density (CS-ac-
tivity/cell protein) remained unchanged. A reduction of cell
size [35] is in line with strong inhibition of protein synthesis
by dexamethasone [36] and cell cycle arrest in G1 (Fig. 5B).
Importantly, Bcl-2 acts downstream of glucocorticoid-regu-
lated events leading to inhibition of cell cycle progression
[5]. (ii) Metabolic arrest could not explain the reduction of
endogenous respiration, since the ratio of uncoupled to
endogenous respiration was high and constant. Metabolicshutdown by reduction of ATP demand would increase
the UCR, whereas substrate limitation would decrease the
scope of activation by FCCP and thus reduce the UCR.
Metabolic arrest has been implicated as a factor resulting in
programmed cell death [11]. Cell cycle arrest in the G1/G0-
phase after growth factor deprivation [11], however, leads to
a reduction of cell size [37] comparable to dexamethasone
treatment. In both cases, the 30–40% decrease in the rate of
cellular oxygen consumption correlates with a similar reduc-
tion of cell size at a conserved UCR. This suggests that the
intensity of aerobic metabolism per unit of cell volume is
maintained, contrary to substrate limitation and metabolic
arrest. Mean cell size is reduced only marginally in freshly
isolated T cells after growth factor withdrawal that is
accompanied with minor changes in oxygen consumption
[38], which further supports the dominant role of cell size in
cellular respiration. Taken together, our quantitative inter-
pretation of cellular respiration points to a highly preserved
mitochondrial function in the early stage of apoptosis in-
duced by dexamethasone or growth factor withdrawal.
Contrary to the effect of dexamethasone, gemcitabine
treatment effectively increased endogenous respiration at
an identical stage of apoptosis. Transient activation of
cellular respiration is possible by induction of permeability
transition and uncoupling. This mechanism is excluded by
our observation of a constant UCR in all treatments, which
argues for a highly preserved quality of mitochondria.
Incorporation of the cytidine analogue dFdC which termi-
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phase (Fig. 5D; see also Ref. [16]). An increase in cell size
and mitochondrial content occurs in aphidicolin-induced
apoptosis in Chinese ovary hamster cells despite cell cycle
arrest [31]. In contrast to the reportedly low function of
newly assembled mitochondria [31], our approach reveals
fully competent mitochondria in terms of coupled respiration
and enzyme activities. In conclusion, the two apoptogenic
drugs exerted opposite effects on cell size and mitochondrial
contents. Cell cycle arrest shifts the size of a growing cell
population depending on the phase distribution. The inter-
mediate size of control cells is in line with a non-synchro-
nized bulk population during logarithmic growth (Fig. 5).
The mitochondrial size and density remain constant through-
out the cell cycle from G1- to the S-phase [12]. The
approximately 2-fold higher protein contents, respiratory
and enzyme activities per cell after treatment with gemcita-
bine versus dexamethasone, therefore, are compatible with
cell cycle arrest in the S- and G1-phase after division and
inhibition of growth (Fig. 6). Any additional drug-specific
effects on the pathophysiology of cells must be evaluated
relative to quantitative changes throughout the cell cycle.
Taken together, mitochondrial injuries remained hardly
detectable relative to the substantial quantitative changes
brought about by alterations in cell size in the present
context of apoptosis. Such significant changes in average
cell size and corresponding mitochondrial content must be
carefully considered not only when interpreting respiratory
activities, but particularly when evaluating fluorescence
signal intensities [12,39,40]. Rather than indicating changes
in mitochondrial membrane potential, the latter may reflect
alterations in the number of mitochondria per cell [41].
Normalization of biochemical changes to cell size, there-
fore, will contribute to clarify the common mechanisms
leading to programmed cell death, by distinguishing be-
tween specific pathophysiological effects of apoptosis and
quantitative changes related to cell cycle arrest.Acknowledgements
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